

According to research published online Oct 31 in the Journal of the Society for Cardiovascular Angiography & Interventions, mechanical thrombectomy (MT) is safe and efficacious in real-world, high-risk patients with pulmonary embolism (PE).
Dr. James M. Horowitz of New York University’s Grossman School of Medicine and colleagues investigated the safety and efficacy of MT for high-risk PE. The study comprised 63 high-risk patients from the multicenter FlowTriever All-comer Registry for Patient Safety and Hemodynamics trial.
The researchers discovered that 47.6 percent of patients had a systolic blood pressure of 90 mm Hg, 46.0 percent needed vasopressors, and 6.3 percent died. 72.6 percent of patients were tachycardic at baseline, 54.5 percent had increased lactate levels of 2.5 mM, and 42.9 percent had a decreased cardiac index of 2 L/min/m2. After MT, my heart rate increased to 93.5 beats per minute. Twenty-five patients (42.4 percent) did not need to stay in the intensive care unit overnight. There were no fatalities or serious adverse events during the first 48 hours, and no fatalities occurred over the 30-day follow-up.
“Our findings highlight the effectiveness of mechanical thrombectomy as a first-line treatment for high-risk pulmonary embolism,” Horowitz said in a statement. “By removing blood clots from the lungs, this procedure can rapidly restore blood flow and prevent fatal complications.”
Several authors revealed connections to the medical technology industry.
For more information: James M. Horowitz et al, Mechanical Thrombectomy for High-Risk Pulmonary Embolism: Insights From the US Cohort of the FLASH Registry, Journal of the Society for Cardiovascular Angiography & Interventions (2023).
DOI: 10.1016/j.jscai.2023.101124
more recommended stories
Key Immune Pathways in Centenarians Identified
Centenarians Offer Clues to Healthy Aging.
Action Video Games and Brain Health: Study Insights
Gaming and Brain Structure: What MRI.
Creatine May Boost Muscle Strength in Alzheimer’s Patients
Creatine Supplementation Shows Promise in Alzheimer’s.
New Drug STF-1623 Shows Promise in Treating Solid Tumors
STF-1623 Transforming ‘Cold’ Tumors into ‘Hot’.
Macrophage Microautophagy Supports Immune Readiness
A Breakthrough in Cellular Recycling Macrophages,.
The Role of α-Glucosidase in Type 2 Diabetes
α-Glucosidase Inhibition: Functional Food Compounds for.
Oral Bacteria Linked to Atherosclerosis
New Evidence Links Viridans Streptococci to.
CDI Test Shows Early Detection Potential in Alzheimer’s
Breakthrough Study Highlights Brain Blood Flow.
Prenatal Chlorpyrifos Exposure and Pediatric Brain Changes
A Growing Concern in Pediatric Neurodevelopment.
Valve Deterioration After TAVI: New Research Insights
The Growing Role of TAVI in.
Leave a Comment